- Kohji Abe
- Head of Imaging Biomarker, Imaging Biomarker, Translational Research Unit, Biomarker R&D Department
Translational research, which bridges exploratory study and clinical development, is necessary for making a go or no-go decision at the earliest possible time or for implementing proof of concept (POC). The utilization of biomarkers, one of the most important methods in translational research, has now become an indispensable streamlining tool in developing pharmaceutical products like implementing a POC or POM (proof of mechanism) and patient stratification.
The imaging biomarker group investigates the pharmacokinetics and pharmacological properties of new drug candidates to estimate the optimum doses of new drugs or assess their efficacy, using imaging technologies widely used in clinical diagnoses, such as positron emission tomography (PET), single photon emission CT (SPECT), or magnetic resonance imaging (MRI). Furthermore, we are searching for new imaging biomarkers that can be used to estimate the intended patient strata or monitor their morbidity along with procedures for measuring and analyzing such markers. With PET, various radioactive compounds, which are referred to as molecular probes, help visualize the in-vivo behavior of the target molecules in a quantitative manner. Therefore, the group not only studies conventional probes, but also tries to find new molecular probes that will act on the target molecules and take measurements of receptor occupancy etc. for the compounds. In this process, based on the results of studies in animal models (ranging from rodents to primates), the utility of the new molecular probes will be assessed using human microdose studies to produce a list as development candidates. In the MRI study, methods to identify disease pathology and pharmacological action are developed for the assessment of candidate compounds. Using functional MRI, imaging markers are being investigated using neural activity or brain networks as indices, particularly in brain function imaging studies.
PET imaging in primate brain
Rat DMN (Default Mode Network)
- 1. Kohji Abe, Nozomi Takai, Kazumi Fukumoto, Natsumi Imamoto, Misato Tonomura, Miwa Ito, Naoki Kanegawa, Katsunori Sakai, Kenji Morimoto, Kenichiro Todoroki and Osamu Inoue
In vivo imaging of reactive oxygen species in mouse brain by using [3H]Hydromethidine as a potential radical trapping radiotracer
J Cereb Blood Flow Metab. 2014 Dec;34(12):1907-13.
- 2. Yuto Kashiwagi, Takemi Rokugawa, Tomomi Yamada, Atsushi Obata, Hiroshi Watabe, Yoshichika Yoshioka and Kohji Abe
Pharmacological MRI Response to a Selective Dopamine Transporter Inhibitor, GBR12909, in Awake and Anesthetized Rats
Synapse. 2015 Apr;69(4):203-12.
- 3. Sotaro Momosaki, Miwa Ito, Hiroko Yamato, Hitoshi Iimori, Hirokazu Sumiyoshi, Kenji Morimoto, Natsumi Imamoto, Tadashi Watabe, Eku Shimosegawa, Jun Hatazawa and Kohji Abe
Longitudinal imaging of the availability of dopamine transporter and D2 receptor in rat striatum following mild ischemia
J Cereb Blood Flow Metab. 2017 Feb;37(2):605-613.
- 4. Nozomi Takai, Natsumi Miyajima, Misato Tonomura, Kohji Abe
Relationship between receptor occupancy and the antinociceptive effect of mu opioid receptor agonists in male rats
Brain Res. 2018 Feb 1;1680:105-109
- 5. Takemi Rokugawa, Haruyo Konishi, Miwa Ito, Hitoshi Iimori, Ryohei Nagai, Eku Shimosegawa, Jun Hatazawa and Kohji Abe
Evaluation of hepatic integrin αvβ3 expression in non-alcoholic steatohepatitis (NASH) model mouse by 18F-FPP-RGD2 PET
EJNMMI Res. 2018 31;8(1):40.